ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Study of the Efficacy of an Investigational Drug in Adult Patients With Non Small-Cell Lung Cancer (NSCLC)

This study has been completed.

Sponsored by: Pfizer
Information provided by: Pfizer
ClinicalTrials.gov Identifier: NCT00034957
  Purpose

The primary goal of the study is to evaluate an investigational drug's effectiveness as a treatment for Non small-cell lung cancer (NSCLC)


Condition Intervention Phase
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Drug: Investigational drug
Phase II

MedlinePlus related topics:   Cancer    Lung Cancer   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment
  Eligibility
Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Other specific inclusion/exclusion criteria may apply. In order to determine eligibility, further examination by the investigator is necessary.

Inclusion Criteria: Eligible patients must be at least 18 years of age with a diagnosis of NSCLC that has gotten worse during or after treatment with platinum-based chemotherapy. Patients must have at least one tumor that can be evaluated by the doctor during the investigational drug treatment. Any side-effects from prior chemotherapy must have subsided, and blood and urine tests must show adequate bone marrow, liver, and kidney function.

Exclusion Criteria: Any of the following will exclude patients from study participation: receipt of more than 1 prior regimen of chemotherapy for NSCLC (repeat of the same chemotherapy at different points in time count as 1 regimen). Irradiation to 25% or more of bone marrow, prior high dose chemotherapy with bone marrow or stem cell support, current participation in other clinical trials, pregnant or breast-feeding women, known HIV-positive or AIDS-related illness.

  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00034957

Locations
United States, California
Research Center    
      Greenbrae, California, United States, 94904-2007
Research Center    
      Berkeley, California, United States, 94704
Research Center    
      Rancho Mirage, California, United States, 92270
Research Center    
      Los Angeles, California, United States, 90048
United States, Illinois
Research Center    
      Chicago, Illinois, United States, 60637-1463
United States, Kentucky
Research Center    
      Louisville, Kentucky, United States, 40202
United States, Massachusetts
Research Center    
      West Boylston, Massachusetts, United States, 01583
United States, Michigan
Research Center    
      Ann Arbor, Michigan, United States, 48109
United States, New Hampshire
Research Center    
      Lebanon, New Hampshire, United States, 03756
United States, Tennessee
Research Center    
      Nashville, Tennessee, United States, 37232-6868
United States, Texas
Research Center    
      Arlington, Texas, United States, 76012
Research Center    
      Dallas, Texas, United States, 75390

Sponsors and Collaborators
Pfizer
  More Information


Study ID Numbers:   196-ONC-0100-005
First Received:   May 2, 2002
Last Updated:   June 23, 2005
ClinicalTrials.gov Identifier:   NCT00034957
Health Authority:   United States: Food and Drug Administration

Keywords provided by Pfizer:
Pharmacia  

Study placed in the following topic categories:
Thoracic Neoplasms
Non-small cell lung cancer
Respiratory Tract Diseases
Lung Neoplasms
Lung Diseases
Carcinoma, Non-Small-Cell Lung
Neoplasms, Glandular and Epithelial
Carcinoma

Additional relevant MeSH terms:
Respiratory Tract Neoplasms
Neoplasms
Neoplasms by Site
Neoplasms by Histologic Type

ClinicalTrials.gov processed this record on November 20, 2008




Links to all studies - primarily for crawlers